PDF(Pubmed)
Abstract：
Brolucizumab has high efficacy in retinal fluid resolution and provides the possibility for longer dosing intervals in the treatment of neovascular age-related macular degeneration. However, brolucizumab has been associated with events of retinal vasculitis and retinal vascular occlusion typically in the presence of other signs of intraocular inflammation (IOI). The purpose of this report is to provide guidance on the use of brolucizumab for neovascular age-related macular degeneration to a global audience.
A literature review was conducted on adverse events related to IOI after administration of brolucizumab in eyes with neovascular age-related macular degeneration.
Possible risk factors for IOI and retinal vascular occlusion after brolucizumab should be considered before administering brolucizumab. Patients who receive brolucizumab should be educated on the symptoms, signs, and time course of IOI after brolucizumab. Before each injection of brolucizumab, physicians should assess the eye for any signs of inflammation and not treat with brolucizumab if inflammation is detected. Treatment of IOI should be prompt and provided with particular attention to the posterior segment.
Careful patient selection, patient education, assessment for inflammation, and intensive treatment of possible inflammation are important when using brolucizumab in patients with neovascular age-related macular degeneration.
A literature review was conducted on adverse events related to IOI after administration of brolucizumab in eyes with neovascular age-related macular degeneration.
Possible risk factors for IOI and retinal vascular occlusion after brolucizumab should be considered before administering brolucizumab. Patients who receive brolucizumab should be educated on the symptoms, signs, and time course of IOI after brolucizumab. Before each injection of brolucizumab, physicians should assess the eye for any signs of inflammation and not treat with brolucizumab if inflammation is detected. Treatment of IOI should be prompt and provided with particular attention to the posterior segment.
Careful patient selection, patient education, assessment for inflammation, and intensive treatment of possible inflammation are important when using brolucizumab in patients with neovascular age-related macular degeneration.
摘要：
Brolucizumab在视网膜液分辨率方面具有高疗效，并为治疗新生血管性年龄相关性黄斑变性提供了更长给药间隔的可能性。然而,brolucizumab与视网膜血管炎和视网膜血管阻塞事件相关,通常存在眼内炎症(IOI)的其他体征.本报告的目的是为全球观众提供布罗珠单抗治疗新生血管性年龄相关性黄斑变性的指导。
对患有新生血管性年龄相关性黄斑变性的眼用Brolucizumab后与IOI相关的不良事件进行了文献综述。
在使用brolucizumab之前，应考虑brolucizumab后IOI和视网膜血管阻塞的可能危险因素。接受brolucizumab的患者应接受症状教育，标志,以及Brolucizumab治疗后IOI的时程。在每次注射brolucizumab之前，医师应评估眼部是否有任何炎症迹象,如果发现炎症,则不应使用brolucizumab治疗.IOI的治疗应迅速进行，并特别注意后段。
精心挑选病人，患者教育,炎症评估，在新生血管性年龄相关性黄斑变性患者中使用brolucizumab时，对可能的炎症进行强化治疗非常重要。
对患有新生血管性年龄相关性黄斑变性的眼用Brolucizumab后与IOI相关的不良事件进行了文献综述。
在使用brolucizumab之前，应考虑brolucizumab后IOI和视网膜血管阻塞的可能危险因素。接受brolucizumab的患者应接受症状教育，标志,以及Brolucizumab治疗后IOI的时程。在每次注射brolucizumab之前，医师应评估眼部是否有任何炎症迹象,如果发现炎症,则不应使用brolucizumab治疗.IOI的治疗应迅速进行，并特别注意后段。
精心挑选病人，患者教育,炎症评估，在新生血管性年龄相关性黄斑变性患者中使用brolucizumab时，对可能的炎症进行强化治疗非常重要。
